Lipella Pharmaceuticals Sells Substantially All Assets in Chapter 11 for $205K Cash + Milestones

summarizeSummary

Lipella Pharmaceuticals received court approval to sell substantially all assets to XRAIY LLC for $205K cash plus up to $3.2M in milestones. The company cautions common stock may have little or no recovery in Chapter 11.

check_boxKey Events · Legal and Risk Events · LIPO

• Asset Sale Approved

  On June 4, 2026, the Bankruptcy Court approved the sale of substantially all assets to XRAIY LLC, encompassing LP Assets (tacrolimus formulation technology) and MRI Assets.

• Purchase Price Terms

  XRAIY LLC will pay $205,000 at closing, plus up to $3.2 million in milestone payments: $200K upon first patient in Phase IIb trial, $1M upon first patient in Phase III, and $2M upon FDA submission.

• Equity Recovery Warning

  Trading in common stock is highly speculative and may bear little or no relationship to actual recovery, if any, for common stockholders in the Chapter 11 case, the company cautions.

• Sale Free and Clear

  Assets are sold free and clear of all liens, claims, and encumbrances; the purchaser is not assuming most liabilities, leaving the estate to distribute proceeds to creditors.

auto_awesomeAnalysis · LIPO · Life Sciences

Since entering Chapter 11 on March 30, 2026, Lipella Pharmaceuticals has secured bankruptcy court approval to sell substantially all of its assets to XRAIY LLC. The transaction provides $205,000 in cash at closing, with up to $3.2 million in additional milestone payments contingent on clinical progress of its LP-310 drug candidate. Critically, the company warns that common stock may have little or no recovery in the bankruptcy, making this a pivotal development for equity holders.